150 related articles for article (PubMed ID: 11758168)
41. Increase in ampC promoter strength due to mutations and deletion of the attenuator in a clinical isolate of cefoxitin-resistant Escherichia coli as determined by RT-PCR.
Tracz DM; Boyd DA; Bryden L; Hizon R; Giercke S; Van Caeseele P; Mulvey MR
J Antimicrob Chemother; 2005 May; 55(5):768-72. PubMed ID: 15761065
[TBL] [Abstract][Full Text] [Related]
42. Investigation of extended-spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli in Korea.
Jeong SH; Bae IK; Kwon SB; Lee JH; Jung HI; Song JS; Jeong BC; Kim SJ; Lee SH
Lett Appl Microbiol; 2004; 39(1):41-7. PubMed ID: 15189286
[TBL] [Abstract][Full Text] [Related]
43. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
44. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
[TBL] [Abstract][Full Text] [Related]
45. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
[TBL] [Abstract][Full Text] [Related]
46. Ultrastructural stages of biofilm development of Escherichia coli on urethral catheters and effects of antibiotics on biofilm formation.
Koseoglu H; Aslan G; Esen N; Sen BH; Coban H
Urology; 2006 Nov; 68(5):942-6. PubMed ID: 17113884
[TBL] [Abstract][Full Text] [Related]
47. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Bethel CR; Hujer AM; Helfand MS; Bonomo RA
FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
[TBL] [Abstract][Full Text] [Related]
48. Detection of OXA-2 group extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli from India.
Bhattacharjee A; Sen MR; Anupurba S; Prakash P; Nath G
J Antimicrob Chemother; 2007 Sep; 60(3):703-4. PubMed ID: 17623688
[No Abstract] [Full Text] [Related]
49. Extension of the hydrolysis spectrum of AmpC beta-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix.
Mammeri H; Poirel L; Nordmann P
J Antimicrob Chemother; 2007 Sep; 60(3):490-4. PubMed ID: 17586561
[TBL] [Abstract][Full Text] [Related]
50. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
[TBL] [Abstract][Full Text] [Related]
51. Emergence of CTX-M beta-lactamase-producing Enterobacteriaceae in Portugal: report of an Escherichia coli isolate harbouring blaCTX-M-14.
Machado E; Coque TM; Cantón R; Sousa JC; Peixe L
Clin Microbiol Infect; 2004 Aug; 10(8):755-7. PubMed ID: 15301680
[TBL] [Abstract][Full Text] [Related]
52. Hyperproduction of inhibitor-susceptible TEM beta-lactamase is responsible for resistance of Serratia marcescens to beta-lactam-beta-lactamase inhibitor combinations.
Zhao WH; Hu ZQ; Chen G; Ito R; Shimamura T
Chemotherapy; 2008; 54(1):31-7. PubMed ID: 18063864
[TBL] [Abstract][Full Text] [Related]
53. The impact of diagnostic delay on the course of septic shock caused by extended-spectrum-beta- lactamase-producing Escherichia coli.
Gashi M; Raka L; Ahmeti S; Gashi S; Dika A; Gashi G
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):846-7. PubMed ID: 19736487
[No Abstract] [Full Text] [Related]
54. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain.
Sorlózano A; Gutiérrez J; Salmerón A; Luna JD; Martínez-Checa F; Román J; Piédrola G
Int J Antimicrob Agents; 2006 Dec; 28(6):532-6. PubMed ID: 17045785
[TBL] [Abstract][Full Text] [Related]
55. Enzymatic assay of beta-lactamase using circular dichroism spectropolarimetry.
Long DM
Anal Biochem; 1997 May; 247(2):389-93. PubMed ID: 9177703
[TBL] [Abstract][Full Text] [Related]
56. The effect of beta-lactamase stability, penetration, and target affinity on the activity of cefazolin, cefamandole, cefoxitin, and cefuroxime.
Harper PB
Clin Ther; 1984; 6(3):310-24. PubMed ID: 6609771
[TBL] [Abstract][Full Text] [Related]
57. Synergistic effect of lipopeptide biosurfactant with antibiotics against Escherichia coli CFT073 biofilm.
Rivardo F; Martinotti MG; Turner RJ; Ceri H
Int J Antimicrob Agents; 2011 Apr; 37(4):324-31. PubMed ID: 21316197
[TBL] [Abstract][Full Text] [Related]
58. Common beta-lactamases inhibit bacterial biofilm formation.
Gallant CV; Daniels C; Leung JM; Ghosh AS; Young KD; Kotra LP; Burrows LL
Mol Microbiol; 2005 Nov; 58(4):1012-24. PubMed ID: 16262787
[TBL] [Abstract][Full Text] [Related]
59. Cefoxitin resistance by a chromosomal cephalosporinase in Escherichia coli.
Takahashi I; Sawai T; Ando T; Yamagishi S
J Antibiot (Tokyo); 1980 Sep; 33(9):1037-42. PubMed ID: 7002896
[TBL] [Abstract][Full Text] [Related]
60. Effects of low-intensity and low-frequency ultrasound combined with tobramycin on biofilms of extended-spectrum beta-lactamases (ESBLs) Escherichia coli.
Hou Y; Yang M; Jiang H; Li D; Du Y
FEMS Microbiol Lett; 2019 Feb; 366(3):. PubMed ID: 30715289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
